Clinical Trial Update: Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED) [Phase 3]

View source ↗

Summary

A Phase 3 study (P05016) comparing 24 weeks versus 48 weeks of Peginterferon alfa-2b plus ribavirin in treatment-naïve chronic hepatitis C (genotype 1) was term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Peginterferon alfa-2b (Peginterferon alfa-2b)
• Ribavirin (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 3 | Status: TERMINATED | Results posted: 2011-02-23